An Analysis of Portfolio and Innovation Policy of Taiwan''s Biopharmaceutical Industry

• Main Authors: Ching-Wen Liu, 劉靜文
• Other Authors: Joseph Z. Shyu
• Format: Others
• Language: zh-TW
• Published: 2003
• Online Access: http://ndltd.ncl.edu.tw/handle/22777717891886305003

碩士 === 國立交通大學 === 科技管理所 === 91 === This thesis reports on a strategic analysis of the development of Taiwan’s biopharmaceutical industry, using a portfolio model to assess competitive and strategic requirements for the development. The portfolio model entails a 2-dimensional analysis, containing technology life-cycle (vertical axis) and the value chain (horizontal). Three research methods used for data collection are literature review, expert interview, and general survey. Result point out that the biopharmaceutical industry is now positioned at the technology acquisition stage of the technology life cycle, and the basic/applied research phase of value chain. The future direction should aim at basic/applied and the clinical phases. Evaluating the Industrial Innovation Requirements and policy tools leads to a conclusion that the most critical categories of policy instruments be Scientific and Technical Development, Education, Governmental purchase, Publicly-owned Enterprises and Finance. The government should organize international biotech exhibition, assist in the acquisition foreign technology to improve quality of domestic R&D, encourage corporations to participate in government sponsored R&D projects, and establish data base platform for needed human resources. Moreover, this research suggests that the government should establish industry-specific capital markets to facilitate the development.